In a strategic move that spans continents, Medela, the globally renowned healthcare company celebrated as North America’s most trusted breastfeeding brand, has disclosed its intent to separate its wound care division into a distinct global entity. This newly emerging wound care enterprise will continue the tradition of providing state-of-the-art wound care solutions, all powered by Medela’s groundbreaking medical vacuum technology.
Central to its portfolio will be Medela’s acclaimed Negative Pressure Wound Therapy (NPWT) product line and the array of associated services.
Meeting Global Wound Care Challenges
Chronic Wounds: An Alarming Global Issue
Chronic, non-healing wounds pose a pressing global public health challenge, imposing substantial physical and economic burdens on both patients and healthcare systems. These chronic wounds encompass a spectrum of conditions, including pressure injuries, diabetic foot ulcers, arterial and venous insufficiency ulcers, traumatic wounds, burns, and post-surgical incisions, among others.
Leveraging Medela’s cutting-edge technologies such as Intelligent Pressure Control and Dynamic Exudate Removal found in Invia systems, a new standard for NPWT has emerged, offering effective and expedited healing, thereby enhancing patients’ quality of life.
Innovations Beyond Borders
Medela and medaxis: Joining Forces
The forthcoming standalone wound care enterprise will seamlessly integrate state-of-the-art wound therapy technologies from medaxis, thus providing unique solutions to accelerate healing and enhance health outcomes.
The Medaxis technology not only promotes neovascularization and tissue growth but also significantly boosts cellular activity and circulation. Moreover, it plays a vital role in reducing bacterial loads. Recognizing its significance, the technology has garnered an FDA Breakthrough Designation, thereby further strengthening the new wound care company’s comprehensive approach to wound healing.
Underpinning this approach is the support of a robust business model and a well-established network, both with a clear focus on catering to a broader audience of healthcare professionals and patients. The pivotal collaboration has been made possible through the active involvement of Medaxis, a Swiss medical technology firm operating under the umbrella of Olle Larsson Holding (OLH).
New Leadership for a New Venture
Jeff Castillo: Appointed CEO of the Standalone Wound Care Company
Effective December 1, Jeff Castillo, the current Executive Vice President of Medela Americas, will take the reins as the CEO of the new wound care company. With a distinguished track record in medical device leadership positions, including roles at industry giants like Johnson & Johnson (J&J), Abbott, and Merz, Castillo brings a wealth of experience, underscored by a deep understanding of the wound care market, particularly the NPWT portfolio. His appointment signifies a perfect alignment of expertise to steer the new autonomous wound care company.
“I am honored and excited to lead the new wound care company,”
“Medela has an enduring legacy founded on remarkable medical vacuum technology. I eagerly anticipate collaborating with these dedicated professionals to redefine the standard of care through wound care solutions driven by Medela’s medical vacuum technology and fresh medical innovations from medaxis.”
A Seamless Transition and Commitment to Customers
The new wound care company will maintain its product shipping operations at Medela’s facility in Elgin, Illinois. Current medaxis staff, along with their leadership, as well as existing members of the Medela wound care team, will transition under the guidance of Jeff Castillo, effective December 1. Medela is resolute in ensuring a smooth transition for its customers to the new wound care entity.
Guided by a commitment to advancing research, observing natural behaviors, and attentively listening to customer needs, Medela translates science into caregiving while nurturing health across generations.
Operating in over 100 countries worldwide, Medela supports millions of mothers, babies, patients, and healthcare professionals. As the healthcare choice for more than 6 million hospitals and homes across the globe, Medela offers leading research-based breast milk feeding and baby products, healthcare solutions for hospitals, and clinical education.
The company is devoted to enhancing health outcomes, simplifying and improving lives, and pioneering breakthroughs that empower mothers, babies, and patients to live life to the fullest.